Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 25088940

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2014 Sep
First author
Heinemann V

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2014 Sep;15(10):1040-1. doi: 10.1016/S1470-2045(14)70360-2.
    note
    Source null
    related pmid
    25088941
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2014 Oct;11(10):560. doi: 10.1038/nrclinonc.2014.141.
    note
    Source null
    related pmid
    25135366
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2014 Dec;15(13):e581. doi: 10.1016/S1470-2045(14)70397-3.
    note
    Source null
    related pmid
    25456372
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2014 Dec;15(13):e581-e582. doi: 10.1016/S1470-2045(14)70400-0.
    note
    Source null
    related pmid
    25456373
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2014 Dec;15(13):e582-e583. doi: 10.1016/S1470-2045(14)70401-2.
    note
    Source null
    related pmid
    25456374
    relationship
    Comment in
  6. citation
    Lancet Oncol. 2014 Dec;15(13):e583-e584. doi: 10.1016/S1470-2045(14)71036-8.
    note
    Source null
    related pmid
    25456375
    relationship
    Comment in

Authors and identifiers

  1. name
    Heinemann V
    type
    Author
  2. name
    von Weikersthal LF
    type
    Author
  3. name
    Decker T
    type
    Author
  4. name
    Kiani A
    type
    Author
  5. name
    Vehling-Kaiser U
    type
    Author
  6. name
    Al-Batran SE
    type
    Author
  7. name
    Heintges T
    type
    Author
  8. name
    Lerchenmüller C
    type
    Author
  9. name
    Kahl C
    type
    Author
  10. name
    Seipelt G
    type
    Author
  11. name
    Kullmann F
    type
    Author
  12. name
    Stauch M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Heinemann V
    type
    Author
  2. name
    von Weikersthal LF
    type
    Author
  3. name
    Decker T
    type
    Author
  4. name
    Kiani A
    type
    Author
  5. name
    Vehling-Kaiser U
    type
    Author
  6. name
    Al-Batran SE
    type
    Author
  7. name
    Heintges T
    type
    Author
  8. name
    Lerchenmüller C
    type
    Author
  9. name
    Kahl C
    type
    Author
  10. name
    Seipelt G
    type
    Author
  11. name
    Kullmann F
    type
    Author
  12. name
    Stauch M
    type
    Author
bibliography ids
  1. nci-bib-65c55a9c678fab62786deee6
book metadata
content sha256
1383f6a4b689de0800bc05fe31381c3ee9e263304ab350ea69cdc8f6e716b1e5
document type
citation
dois
  1. 10.1016/S1470-2045(14)70330-4
electronic publication date
display
2014 Jul 31
precision
day
year
2014
evidence scope
bibliographic_metadata_only
id
pubmed:25088940
immutable id
pubmed:25088940@1383f6a4b689de0800bc05fe31381c3ee9e263304ab350ea69cdc8f6e716b1e5
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
10
name
The Lancet. Oncology
nlm unique id
100957246
pages
1065-75
volume
15
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2014 Sep;15(10):1040-1. doi: 10.1016/S1470-2045(14)70360-2.
    note
    Source null
    related pmid
    25088941
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2014 Oct;11(10):560. doi: 10.1038/nrclinonc.2014.141.
    note
    Source null
    related pmid
    25135366
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2014 Dec;15(13):e581. doi: 10.1016/S1470-2045(14)70397-3.
    note
    Source null
    related pmid
    25456372
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2014 Dec;15(13):e581-e582. doi: 10.1016/S1470-2045(14)70400-0.
    note
    Source null
    related pmid
    25456373
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2014 Dec;15(13):e582-e583. doi: 10.1016/S1470-2045(14)70401-2.
    note
    Source null
    related pmid
    25456374
    relationship
    Comment in
  6. citation
    Lancet Oncol. 2014 Dec;15(13):e583-e584. doi: 10.1016/S1470-2045(14)71036-8.
    note
    Source null
    related pmid
    25456375
    relationship
    Comment in
outcomes validated
false
pmid
25088940
provenance
batch id
69903be8ceab8801c81a
provider
NCBI PubMed ESummary
record sha256
bcfdae943beb70ea52b41b6410e99df7b2dc4a9ea000c90c7505900727fc5995
response sha256
1e367491c3c459a93f45b3db99ca1f9293ed2287c48bdf758bb088ffcd7c96eb
retrieved at
2026-09-09T23:47:05.208886+00:00
publication date
display
2014 Sep
precision
month
year
2014
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Journal Article
  4. Multicenter Study
  5. Randomized Controlled Trial
  6. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/25088940/
title
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

Preserved source evidence · Independent clinical review pending · Not medical advice